Collegium Pharmaceutical Inc [COLL] stock prices are up 4.03% to $42.3 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The COLL shares have gain 17.50% over the last week, with a monthly amount glided 27.37%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Collegium Pharmaceutical Inc [NASDAQ: COLL] stock has seen the most recent analyst activity on January 10, 2025, when Needham upgraded its rating to a Buy but kept the price target unchanged to $46 for it. Previously, H.C. Wainwright upgraded its rating to Buy on July 30, 2024, and kept the price target unchanged to $47. On June 07, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $44 on the stock. Piper Sandler downgraded its rating to a Neutral but stick to its price target of $39 on May 10, 2024. Needham downgraded its rating to a Hold. Jefferies downgraded its rating to Hold for this stock on January 04, 2024, and upped its price target to $37. In a note dated August 25, 2023, Needham reiterated an Buy rating on this stock and boosted its target price from $35 to $36.
The stock price of Collegium Pharmaceutical Inc [COLL] has been fluctuating between $23.23 and $41.81 over the past year. Currently, Wall Street analysts expect the stock to reach $40.25 within the next 12 months. Collegium Pharmaceutical Inc [NASDAQ: COLL] shares were valued at $42.3 at the most recent close of the market. An investor can expect a potential drop of -4.85% based on the average COLL price forecast.
Analyzing the COLL fundamentals
The Collegium Pharmaceutical Inc [NASDAQ:COLL] reported sales of 757.07M for trailing twelve months, representing a surge of 31.42%. Gross Profit Margin for this corporation currently stands at 0.57% with Operating Profit Margin at 0.21%, Pretax Profit Margin comes in at 0.11%, and Net Profit Margin reading is 0.08%. To continue investigating profitability, this company’s Return on Assets is posted at 0.04, Equity is 0.24 and Total Capital is 0.14. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.96.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 40.91 points at the first support level, and at 39.51 for the second support level. However, for the 1st resistance point, the stock is sitting at 43.38, and for the 2nd resistance point, it is at 44.45.
Ratios To Look Out For
It’s worth pointing out that Collegium Pharmaceutical Inc [NASDAQ:COLL]’s Current Ratio is 1.36. As well, the Quick Ratio is 1.27, while the Cash Ratio is 0.33. Considering the valuation of this stock, the price to sales ratio is 1.77, the price to book ratio is 4.86 and price to earnings (TTM) ratio is 26.33.
Transactions by insiders
Recent insider trading involved Tupper Colleen, EVP & Chief Financial Officer, that happened on Nov 06 ’25 when 30000.0 shares were sold. Officer, Tupper Colleen completed a deal on Nov 06 ’25 to buy 30000.0 shares. Meanwhile, EVP and Chief Medical Officer Smith Thomas B sold 17478.0 shares on Aug 29 ’25.
